NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

§ 01 Executive Snapshot

What: NervGen Pharma reports Q1 2026 financial results and business updates, including FDA meeting outcomes and Nasdaq listing.
Who: NervGen Pharma Corp., led by CEO Adam Rogers, and newly appointed leadership team members.
Why it matters: The successful alignment with the FDA on study parameters for the NVG-291 registrational study represents a significant step towards advancing treatment options for spinal cord injury (SCI).

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia.
The RESTORE study is on track for initiation in mid-2026, with site activation underway.
Independent, blinded biomechanical gait analyses of the CONNECT SCI study remain ongoing, with results anticipated in 2Q 2026.
NervGen successfully listed on Nasdaq under the symbol 'NGEN' on January 8, 2026, and voluntarily delisted from the TSX Venture Exchange.
Cash and investments as of March 31, 2026, totaled $16.6 million.

NervGen is positioned as a clinical-stage biopharmaceutical company focusing on neuroreparative therapeutics, specifically targeting spinal cord injuries, which currently have limited treatment options.
The development of NVG-291 is part of a broader strategy to transform the treatment landscape for neurotraumatic and neurologic conditions through innovative pharmacologic approaches.

Immediate market implications include potential leadership in the neurotherapeutics space, especially if NVG-291 proves effective in clinical trials.
Long-term implications may involve establishing new standards of care for spinal cord injury and related conditions, significantly impacting patient quality of life and healthcare practices.

Potential risks include challenges in clinical trial execution, including the ability to meet regulatory requirements and timelines.
Competition from other biopharmaceutical companies developing treatments for SCI and other neurotraumatic conditions could hinder market penetration.

The initiation of the RESTORE study in mid-2026 will be a critical milestone for NervGen and a key indicator of the company's progress.
Results from the biomechanical gait analyses in 2Q 2026 will provide important data on the effectiveness of NVG-291 and its potential for further development.